RELEASE OF THE 2CUREX AB (PUBL) ANNUAL REPORT

June 28 | 2024

THIS PRESS RELEASE IS AN ENGLISH TRANSLATION OF THE LEGALLY BINDING SWEDISH PRESS RELEASE: “PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (publ)”.

The Annual Report for 2023 for 2cureX AB (publ), 559128-0077, is now available.

The annual report, along with the auditor's report for 2cureX AB and the 2cureX group, as well as complete proposals for resolutions and proxy forms, can be accessed at the company's office at 2cureX, Fruebjergvej 3, 2100 Copenhagen, Denmark, and on the company's website (www.2curex.com).

Malmö in May 2024
2cureX AB (publ)
The Board of Directors

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB